BRNS - Company ID 0001828185
The table below shows Barinthus Biotherapeutics plc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | - | - | $14.97M | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $3.59M | $5.39M | $7.95M | $8.29M | $11.14M | $11.66M |
| SG&A |
Barinthus Biotherapeutics plc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $14.97M in fiscal 2024. Over the 6 fiscal years shown, annual revenue declined from $4.82M (FY 2020) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.53M |
| $5.17M |
| $15.38M |
| $12.64M |
| $13.42M |
| $7.20M |
| Operating income | -$6.08M | -$15.07M | -$23.32M | -$20.60M | -$9.38M | -$18.29M |
| Income tax | -$16.00K | -$71.00K | -$25.00K | -$22.00K | -$3.00K | -$7.00K |
| Net income | -$5.53M | -$14.57M | -$21.12M | -$19.65M | -$8.11M | -$16.93M |
| EPS (diluted) | -$0.14 | -$0.36 | -$0.52 | -$0.49 | -$0.21 | -$0.43 |